Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

UroGen Pharma Q1 EPS $(0.97) Misses $(0.87) Estimate, Sales $18.78M Miss $21.38M Estimate

Author: Benzinga Newsdesk | May 13, 2024 08:01am

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 25.38 percent increase over losses of $(1.30) per share from the same period last year. The company reported quarterly sales of $18.78 million which missed the analyst consensus estimate of $21.38 million by 12.16 percent. This is a 9.24 percent increase over sales of $17.19 million the same period last year.

Posted In: URGN